ABBV
Stock Details
ABBV is AbbVie Inc.'s stock. Stock exchange NYSE (Currency USD). Average price in 50 days is 157.28$. Average daily volumn in 3 months 7.34M. Market cap 267.51B
Stock symbol : ABBV. Exchange : NYSE. Currency : USD Lastest price : 150.00$. Total volume : 8.25M. Market state CLOSED Click reload if you want to check the lastest price on market!!!
AbbVie Inc. (ABBV)
Last Price
150.00$Change
-0.57Volume
8.25M
| Previous Close | 150.57 |
| Open | 149.52 |
| Day Range | 147.75-150.05 |
| Bid | 150.00 x 800 |
| Ask | 155.00 x 1k |
| Volume | 8.25M |
| Average Volume | 7.34M |
| Market Cap | 267.51B |
| Beta | 0.81 |
| 52 Week Range | 105.56-175.91 |
| Trailing P/E | 21.52 |
| Foward P/E | 12.50 |
| Dividend (Yield %) | 3.75% |
| Ex-Dividend Date | 2022-04-14 |
Financial Details
Organization
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behรงet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCL... EXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Market Cap:
267.51BRevenue:
56.2BTotal Assets:
146.53BTotal Cash:
9.75B
News about "AbbVie Inc."
What Kind Of Shareholders Hold The Majority In AbbVie Inc.'s (NYSE:ABBV) Shares?
Source from : YAHOO!Finance - 1 days ago
If you want to know who really controls AbbVie Inc. ( NYSE:ABBV ), then you'll have to look at the makeup of its ...See details»
ABBVIE INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of AbbVie Inc. - A
Source from : ์ํฌ๋กํฌ - 17 hours ago
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (โKSFโ), announces that KSF has commenced an investigation into AbbVie Inc. (NYSE: ...See details»
AbbVie's Correction Appears to Be Over: Here's Where the Stock Could Be Headed
Source from : TheStreet.com - 2 days ago
Recently, ABBV pulled back from an April high but the correction is showing signs it is over. Should you be a buyer? Let's check the charts. In the daily bar chart of ABBV, below, we can see that the ...See details»
Here is what you need to look for: AbbVie Inc. (ABBV)
Source from : investchronicle - 4 days ago
AbbVie Inc. (ABBV) is priced at $148.03 after the most recent trading session. At the very opening of the session, the stock price was $151.65 and reached a high price of $152.00, prior to closing the ...See details»
AbbVie Inc. Investors: Last Days to Actively Participate in the Class Action Lawsuit; Portnoy Law Firm
Source from : FOX8 Cleveland - 2 days ago
The Portnoy Law Firm advises AbbVie Inc. (โAbbVieโ or the โCompanyโ) (NYSE: ABBV) investors that a class action filed on behalf of investors that purchased Celsius shares between April 30, 2021 and ...See details»
ABBV LAWSUIT ALERT: Levi & Korsinsky Notifies AbbVie Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
Source from : FOX31 Denver - 2 days ago
ABBVย investors may also contact Joseph E. Levi, Esq. via email atย [email protected]ย or by telephone at (212) 363-7500. CASE DETAILS: The filed complaint alleges that defendants made false ...See details»
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AbbVie Inc. - ABBV
Source from : Associated Press - 3 days ago
Pomerantz LLP is investigating claims on behalf of investors of AbbVie Inc. (โAbbVieโ or the โCompanyโ) (NYSE: ABBV). Such inves ...See details»
AbbVie Inc.: Reaffirming BUY with target of $165
Source from : YAHOO!Finance - 3 days ago
Find the latest AbbVie Inc. (ABBV) stock forecast based on top analyst's estimates, plus more investing and trading data from Yahoo Finance ...See details»
AbbVie Inc. (NYSE:ABBV) Vice Chairman Michael Severino Sells 100,000 Shares
Source from : ETF Daily News - 17 days ago
AbbVie Inc. has a fifty-two week low of $105.56 and a fifty-two week high of $175.91. The company has a 50-day simple moving average of $157.51 and a 200-day simple moving average of $139.45.See details»
Here is What to Know Beyond Why AbbVie Inc. (ABBV) is a Trending Stock
Source from : Nasdaq - 23 days ago
AbbVie (ABBV) is one of the stocks most watched ... of the author and do not necessarily reflect those of Nasdaq, Inc. Zacks is the leading investment research firm focusing on stock research ...See details»
AbbVie Inc. (NYSE:ABBV) Given Consensus Rating of โBuyโ by Analysts
Source from : ETF Daily News - 15 days ago
AbbVie Inc. (NYSE:ABBV โ Get Rating) has received a consensus recommendation of โBuyโ from the nineteen brokerages that are covering the company, Marketbeat Ratings reports. Five research ...See details»
ABBV LAWSUIT: The Law Offices of Vincent Wong Notify Investors of a Class Action Lawsuit Involving AbbVie Inc.
Source from : Barron's - 4 days ago
The Law Offices of Vincent Wong announce that a class action lawsuit has commenced in the on behalf of investors who purchased AbbVie Inc. ("AbbVie") (NYSE: ABBV) between April 30, 2021 and August 31, ...See details»
AbbVie: Q1 2022 Results Dampen Enthusiasm And Test Management's Growth Plans
Source from : Seeking Alpha - 28 days ago
Yesterday after market close, AbbVie Inc. (NYSE:ABBV) - currently the U.S.' third-largest pharmaceutical company by market cap, behind only Johnson & Johnson (JNJ) and Pfizer (PFE), announced its ...See details»
AbbVie Inc. (ABBV) Reports First-Quarter 2022 Financial Results
Source from : MarketWatch - 29 days ago
AbbVie (NYSE:ABBV) announced financial results for the first quarter ended March 31, 2022. โThis year is off to a strong start. Our first quarter results highlight the diversity of our portfolio ...See details»